There are an estimated 650,000 cases of dementia in Canada right now. The last 20 years of research into the treatment of Alzheimer’s have been, as one expert put it, “agonizing.” But a new drug was approved in the United States and is being tested in Canada to see if it can delay or slow the progression of Alzheimer’s symptoms. And it’s giving researchers and patients some hope that a breakthrough could be on the way.
Kelly Grant, health reporter for The Globe, has been looking at this drug more closely. She’s on the show today to tell us what these trials mean for patients and the future of Alzheimer’s research.
Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com
Why running is more popular than ever
Sudan and the neglected wars
The biggest EV investment in Canada yet
City Space: Vancouver’s Chinatown fights gentrification
The call to disband the Thunder Bay police
How Hong Kong is cracking down on dissent
As conflict rages in Gaza, a ‘silent war’ in the West Bank
The capital gains tax, explained
ArriveCan and the government’s outsourcing problem
The stakes of India’s election as Modi seeks third term
What the 2024 federal budget means for you
City Space: How Halifax’s unhoused crisis got so bad
What we’ve learned from the foreign interference inquiry
Former health minister Jane Philpott’s plan to save health care
Why major economies are trying to woo Vietnam
How seafood from North Korean forced labour ends up in Canada
The big business bet on psychedelic drugs
The deadly challenges of getting aid into Gaza
School boards take on social media giants
Create your
podcast in
minutes
It is Free
Up First
The Daily
Morning Wire
Today, Explained
Dobré ráno | Denný podcast denníka SME